Growth factors in the therapy of myelodysplasia: biological aspects.
Growth factors (GF) are reported to play an important role in the therapy of myelodisplastic syndromes (MDS). After in vitro administration a consistent group of MDS may respond to GF but the possibility of differentiation, regulation or expansion of myelodisplastic clones following GF therapy is still a question to be answered as their optimum dose and combinations. To validate if in vivo treatment with GF, may promote the regulation or the recovery of myelopoiesis and/or modify the clonality of the responses, we gave G-CSF after intensive chemotherapy in high risk MDS and acute leukemia evolving from MDS patients. According to our data the use of G-CSF after intensive chemotherapy may improve the CR rate without increase of leukemic transformation. However the answer were clonal and the remission duration remained very short so we suggest to utilize this time to perform other therapeutic strategies such as, when possible, the BMT.
Bonfichi
M
M
Istituto di Ematologia, Università di Pavia-IRCCS Policlinico S. Matteo, Italy.
Astori
C
C
Alessandrino
E P
EP
Bernasconi
P
P
Balduini
A
A
Castagnola
C
C
Brusamolino
E
E
Pagnucco
G
G
Canevari
A
A
Trucco
P
P
Bernasconi
C
C
D000328:Adult; D000368:Aged; D016207:Cytokines / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006133:Growth Substances / Q000627:therapeutic use*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000494:pharmacology
D016207:Cytokines; D006133:Growth Substances; D011994:Recombinant Proteins